Anti-EDG2 /LPA-1 antibody
5
(2 Reviews)
|
(19 Publications)
Rabbit Polyclonal EDG2 /LPA-1 antibody. Suitable for WB and reacts with Rat, Human, Mouse samples. Cited in 19 publications.
View Alternative Names
EDG2, LPA1, LPAR1, Lysophosphatidic acid receptor 1, LPA receptor 1, LPA-1, Lysophosphatidic acid receptor Edg-2
- WB
Supplier Data
Western blot - Anti-EDG2 /LPA-1 antibody (AB23698)
All lanes:
Western blot - Anti-EDG2 /LPA-1 antibody (ab23698)
Lane 1:
Solubilised Mouse Liver at 50 µg
Lane 2:
A549 Cell Lysate at 40 µg
Lane 3:
Rat liver lysate at 40 µg
Predicted band size: 41 kDa
false
- WB
CiteAb
Western blot - Anti-EDG2 /LPA-1 antibody (AB23698)
EDG2 /LPA-1 western blot using anti-EDG2 /LPA-1 antibody ab23698. Publication image and figure legend from Wang, H., Tu, S., et al., 2019, Evid Based Complement Alternat Med, PubMed 31781264.
ab23698 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab23698 please see the product overview.
Berberine alters the expression levels of K-ras and c-Raf, as well as the phosphorylation levels of ERK1/2 and p-38 of FLS-RA. (a, b) Berberine treatment at 12.5 and 25 μM for 24 h downregulates the expression of K-ras and ATX, as detected by RT-PCR. (c) Berberine makes no difference to the expression of LPA1, as measured by western blot. (d) The expression levels of c-Raf, P-p38, P-JNK, and P-ERK1/2 are measured through western blot. Berberine treatment for 24 h downregulates the expression of P-p38 (e), P-ERK1/2 (f), and c-Raf (h) in a dose-dependent manner. (g) The phosphorylation level of JNK shows no significant difference before and after berberine treatment. *p < 0.05; ***p < 0.001. Ctrl, control group; ATX, autotaxin; and FLS-RA, fibroblast-like synovial cells of rheumatoid arthritis.
false
Reactivity data
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
EDG2/LPA-1 influences several cellular processes including cell proliferation migration and survival. It does not function as part of a larger complex; instead it activates intracellular signaling cascades upon LPA binding. This activation leads to downstream effects that regulate processes like cytoskeletal reorganization and gene expression. Its influence extends to immune response modulation making it significant in understanding cellular behavior and communication.
Pathways
EDG2/LPA-1 is important in the mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K/AKT) signaling pathways. These pathways affect cell growth survival and metabolism showcasing the receptor's importance in cellular regulation. Through these pathways EDG2 interacts with multiple proteins including RAC1 a small GTPase involved in cytoskeletal organization and various kinase enzymes that facilitate signal transduction.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (19)
Recent publications for all applications. Explore the full list and refine your search
Cells 13: PubMed38995003
2024
Applications
Unspecified application
Species
Unspecified reactive species
Glia 71:945-956 PubMed36495059
2022
Applications
Unspecified application
Species
Unspecified reactive species
Biomolecules 12: PubMed36551233
2022
Applications
Unspecified application
Species
Unspecified reactive species
International journal of molecular sciences 23: PubMed36142408
2022
Applications
Unspecified application
Species
Unspecified reactive species
ASN neuro 14:17590914221083203 PubMed35593118
2022
Applications
Unspecified application
Species
Unspecified reactive species
The Journal of clinical investigation 132: PubMed35166239
2022
Applications
Unspecified application
Species
Unspecified reactive species
Molecules (Basel, Switzerland) 26: PubMed34684879
2021
Applications
Unspecified application
Species
Unspecified reactive species
International journal of molecular sciences 22: PubMed34639115
2021
Applications
Unspecified application
Species
Unspecified reactive species
Evidence-based complementary and alternative medic 2019:2580207 PubMed31781264
2019
Applications
Unspecified application
Species
Unspecified reactive species
Therapeutic advances in medical oncology 11:1758835919875319 PubMed31692673
2019
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com